Should I buy or sell Bolt Biotherapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BOLT shares. View BOLT analyst ratings or view top-rated stocks .

What is Bolt Biotherapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12-month price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 509.3% from the stock's current price. View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts .

How have BOLT shares performed in 2023?

Bolt Biotherapeutics' stock was trading at $1.30 at the start of the year. Since then, BOLT shares have decreased by 28.5% and is now trading at $0.9301. View the best growth stocks for 2023 here .

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our BOLT earnings forecast .

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.06. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $1.60 million. Bolt Biotherapeutics had a negative net margin of 990.43% and a negative trailing twelve-month return on equity of 47.56%.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA) , Ampliphi Biosciences (APHB) , Arbutus Biopharma (ABUS) , Aurora Cannabis (ACBFF) , AcelRx Pharmaceuticals (ACRX) , Aldeyra Therapeutics (ALDX) , Apellis Pharmaceuticals (APLS) , Aquinox Pharmaceuticals (AQXP) .

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Newtyn Management LLC (2.69%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP, Vivo Capital Viii, Llc and William P Quinn . View institutional ownership trends .

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Bolt Biotherapeutics Stock Price, News & Analysis (NASDAQ:BOLT)

$0.93

+0.02 (+2.20%)

(As of 12/5/2023 ET)

Compare

Today's Range: $0.92
▼
$0.95
50-Day Range: $0.85
▼
$1.07
52-Week Range: $0.84
▼
$2.03

Volume: 227,845 shs
Average Volume: 163,647 shs
Market Capitalization: $35.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Bolt Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 509.3% Upside
$5.67 Price Target
Short Interest: Bearish
6.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.66
Based on 2 Articles This Week
Insider Trading: Selling Shares
$125,191 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.78) to ($1.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

390th out of 948 stocks

Biotechnology Industry

12th out of 46 stocks

3.3

Analyst's Opinion

Consensus Rating
Bolt Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.67, Bolt Biotherapeutics has a forecasted upside of 509.3% from its current price of $0.93.
Amount of Analyst Coverage
Bolt Biotherapeutics has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.72% of the float of Bolt Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Bolt Biotherapeutics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Bolt Biotherapeutics has recently increased by 2.50%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Bolt Biotherapeutics does not currently pay a dividend.
Dividend Growth
Bolt Biotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BOLT.

1.9

News and Social Media Coverage

News Sentiment
Bolt Biotherapeutics has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Bolt Biotherapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for BOLT on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bolt Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $125,191.00 in company stock.
Percentage Held by Insiders
28.40% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
73.56% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.78) to ($1.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bolt Biotherapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bolt Biotherapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bolt Biotherapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

BOLT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BOLT Stock News Headlines

December 5, 2023 | finance.yahoo.com

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

November 28, 2023 | americanbankingnews.com

Bolt Biotherapeutics (NASDAQ:BOLT) Shares Cross Below Two Hundred Day Moving Average of $1.26

December 6, 2023 | Edge On The Street (Ad)

U.S. Military Defense Fails Without Vanadium?

The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.

November 11, 2023 | markets.businessinsider.com

Promising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt Biotherapeutics

November 9, 2023 | morningstar.com

Bolt Biotherapeutics Inc Ordinary Shares BOLT

November 9, 2023 | finance.yahoo.com

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

October 23, 2023 | finance.yahoo.com

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

October 17, 2023 | finance.yahoo.com

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

December 6, 2023 | Edge On The Street (Ad)

U.S. Military Defense Fails Without Vanadium?

September 28, 2023 | finance.yahoo.com

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

September 5, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Participate in September Investor Conferences

August 3, 2023 | msn.com

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates

June 17, 2023 | finance.yahoo.com

US0977021049.SG - Bolt Biotherapeutics Inc.

May 26, 2023 | markets.businessinsider.com

Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright

May 13, 2023 | msn.com

SVB Leerink Upgrades Bolt Biotherapeutics (BOLT)

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy Recommendation

May 12, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)

May 12, 2023 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

April 26, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

April 11, 2023 | finance.yahoo.com

Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year

March 30, 2023 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 14, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

January 21, 2023 | reuters.com

BOLT.O - | Stock Price & Latest News | Reuters

January 4, 2023 | finance.yahoo.com

Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

November 2, 2022 | finance.yahoo.com

Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year

November 1, 2022 | finance.yahoo.com

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

September 10, 2022 | morningstar.com

Bolt Biotherapeutics Inc Ordinary Shares

See More Headlines

Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BOLT
CUSIP: 09769810
CIK: 354655
Web: www.boltbio.com
Phone: 650-665-9295
Fax: N/A
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.67
High Stock Price Target: $8.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +509.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,100,000.00
Net Margins: -990.43%
Pretax Margin: -990.43%
Return on Equity: -47.56%
Return on Assets: -35.64%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 6.69
Quick Ratio: 6.69

Sales & Book Value

Annual Sales: $5.73 million
Price / Sales: 6.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.55 per share
Price / Book: 0.20

Miscellaneous

Outstanding Shares: 37,970,000
Free Float: 27,184,000
Market Cap: $35.32 million
Optionable: Not Optionable
Beta: 0.71

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Randall C. Schatzman Ph.D. (Age 68)
CEO & Director
Comp: $829.32k
Dr. Edgar George Engleman M.D. (Age 77)
Founder & Independent Director
Comp: $38.75k
Mr. William P. Quinn (Age 52)
CFO & Secretary
Comp: $594.56k
Mr. Grant Yonehiro C.F.A. (Age 59)
M.B.A., Chief Business Officer
Comp: $544.71k
Dr. Edith A. Perez M.D. (Age 66)
Chief Medical Officer
Comp: $668.32k
Mr. Wesley Burwell
VP & Head of Human Resources
Dr. Nathan Ihle Ph.D.
Senior Vice President of Pharmaceutical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BOLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BOLT shares.
View BOLT analyst ratings or view top-rated stocks.
What is Bolt Biotherapeutics' stock price target for 2024?: 3 Wall Street research analysts have issued 12-month price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 509.3% from the stock's current price.
View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts.
How have BOLT shares performed in 2023?: Bolt Biotherapeutics' stock was trading at $1.30 at the start of the year. Since then, BOLT shares have decreased by 28.5% and is now trading at $0.9301.
View the best growth stocks for 2023 here.
When is Bolt Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BOLT earnings forecast.
How were Bolt Biotherapeutics' earnings last quarter?: Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.06. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $1.60 million. Bolt Biotherapeutics had a negative net margin of 990.43% and a negative trailing twelve-month return on equity of 47.56%.

What other stocks do shareholders of Bolt Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).
When did Bolt Biotherapeutics IPO?: (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.
Who are Bolt Biotherapeutics' major shareholders?: Bolt Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Newtyn Management LLC (2.69%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP, Vivo Capital Viii, Llc and William P Quinn.
View institutional ownership trends.
How do I buy shares of Bolt Biotherapeutics?: Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BOLT) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial